Inhibition of the MAPK pathway in BRAFi-resistant tumors restored tumor infiltration and maturation of CD103+ DCs, reduced suppressive myeloid cells, increased T cell infiltration, and re-sensitize cross-resistant tumors to immunotherapy. The gene discussed is ITGAE; the disease is neoplasm.